Sodium Succinate

Summary

Sodium Succinate (CHEMBL1200345) is an approved small molecule; indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 140.07 Da · C4H5NaO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200345
Name	Sodium Succinate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23690498
Molecular formula	C4H5NaO4
Molecular weight	140.07
InChIKey	KZQSXALQTHVPDQ-UHFFFAOYSA-M

SMILES: C(CC(=O)[O-])C(=O)O.[Na+]

IUPAC name: sodium 4-hydroxy-4-oxobutanoate

Also known as: Anhydrous sodium succinate, Butanedioic acid disodium salt, Disodium succinate, FEMA NO. 3277, Sodium succinate, Sodium succinate anhydrous, Sodium succinate hexahydrate, anhydrous, Succinic acid disodium salt, SODIUM SUCCINATE

Patent coverage: 1,462 distinct patent families (3,185 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,024 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03401398	PHASE3	RECRUITING	Stress Hydrocortisone In Pediatric Septic Shock

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).